Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) Read
Post# of 62
(Total Views: 340)
Posted On: 04/01/2019 4:22:01 PM
Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) Readies Online Sales Strategy for New InterceptCS Cold Sore Prevention Device
- THRBF offers an IoT- and Bluetooth-enabled device for cold-sore prevention
- Its sales strategy is part of the company’s larger focus on developing products for the dermatology market
- THRBF’s proprietary technology is designed to prevent cold sores in the OTC sector, which is projected to record significant sales growth
Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) is offering a new generation of technology in the burgeoning skin care market. The company is specifically planning to target sales growth for its high gross-margin InterceptCS* cold sore prevention device with a new website, social media campaign and online sales strategy (http://nnw.fm/f5cvQ).
THRBF’s new InterceptCS is a class II medical device that works through three 30-second treatments and offers multi-use activators. Therma Bright’s strategy is to market the product online through distributors and a new social media campaign, as well as on its new website at www.ColdSores.com.
Toronto-based THRBF offers first-rate medical devices for dermatological needs. The company focuses on proprietary technology in the OTC pain-free and noninvasive sectors, and it has received class II medical device status from the U.S. Food and Drug Administration (FDA). Therma Bright also markets TherOZap, an insect-bite treatment device.
The dermatology market is estimated to reach $22.6 billion in the United States by 2028, according to GMR Data (http://nnw.fm/E5lYd).
* Based on a double-blind placebo study, InterceptCS is approved for the claim, “For prevention of cold sores when used within three hours of the onset of the prodrome,” by Health Canada. InterceptCS is not approved by the United States FDA for any claim of clinical indication, clinical efficac, and/or cure or prevention of disease.
For more information, visit the company’s website at www.ThermaBright.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- THRBF offers an IoT- and Bluetooth-enabled device for cold-sore prevention
- Its sales strategy is part of the company’s larger focus on developing products for the dermatology market
- THRBF’s proprietary technology is designed to prevent cold sores in the OTC sector, which is projected to record significant sales growth
Therma Bright Inc. (TSX.V: THRM) (OTC: THRBF) is offering a new generation of technology in the burgeoning skin care market. The company is specifically planning to target sales growth for its high gross-margin InterceptCS* cold sore prevention device with a new website, social media campaign and online sales strategy (http://nnw.fm/f5cvQ).
THRBF’s new InterceptCS is a class II medical device that works through three 30-second treatments and offers multi-use activators. Therma Bright’s strategy is to market the product online through distributors and a new social media campaign, as well as on its new website at www.ColdSores.com.
Toronto-based THRBF offers first-rate medical devices for dermatological needs. The company focuses on proprietary technology in the OTC pain-free and noninvasive sectors, and it has received class II medical device status from the U.S. Food and Drug Administration (FDA). Therma Bright also markets TherOZap, an insect-bite treatment device.
The dermatology market is estimated to reach $22.6 billion in the United States by 2028, according to GMR Data (http://nnw.fm/E5lYd).
* Based on a double-blind placebo study, InterceptCS is approved for the claim, “For prevention of cold sores when used within three hours of the onset of the prodrome,” by Health Canada. InterceptCS is not approved by the United States FDA for any claim of clinical indication, clinical efficac, and/or cure or prevention of disease.
For more information, visit the company’s website at www.ThermaBright.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)